Can your doctor prescribe Mounjaro for weight loss?

What NICE's recommendation actually means for prescribing

When NICE recommended tirzepatide in Technology Appraisal TA1026, published in December 2024, it did more than endorse the medicine. It gave UK prescribers a clear clinical framework. Adults with a BMI of 35 or above plus at least one weight-related comorbidity meet the primary threshold; that drops by 2.5 kg/m² for certain ethnic backgrounds under UK guidance. The trial data underpinning that recommendation is substantial. In SURMOUNT-1 (2,539 adults with obesity), participants on the 15 mg dose lost around 20–21% of body weight on average over 72 weeks, figures that helped shift clinical opinion about how effective a medicine in this class could be.

The recommendation does not guarantee a prescription. NICE sets a population-level recommendation; every prescriber then applies clinical judgement to the person in front of them. Contraindications, current medicines, medical history and lifestyle context all form part of that assessment. If you have a history of pancreatitis, certain thyroid conditions, or are pregnant, breastfeeding or hoping to conceive, Mounjaro is not appropriate regardless of BMI. The medicine holds a Black Triangle (▼) status with the MHRA, meaning it is subject to additional post-approval monitoring, another reason clinical oversight is not optional.

Worth knowing: NICE's recommendation covers adults with at least one weight-related condition at BMI 35 or above for NHS commissioning. The medicine's licence itself covers a broader group (BMI 30 or above, or 27 or above with a qualifying condition) and it is this licensed range that applies to private prescriptions.

Can your GP prescribe Mounjaro on the NHS right now?

Technically yes, but the practical answer is more complicated. NHS England has been rolling out tirzepatide in phases. From June 2025, the first cohort became eligible: adults with a BMI of 40 or above who have four or more specific weight-related conditions, including type 2 diabetes, cardiovascular disease, high blood pressure, dyslipidaemia or obstructive sleep apnoea. A second cohort (BMI 35–39.9 with four or more of those conditions) became eligible from June 2026. Further phases are expected around March 2027.

From April 2026 GP practices may prescribe under the new GP contract, but participation is optional. Some practices are active; others are not yet set up. Every NHS patient also needs to engage with wraparound diet and activity support as part of the programme. If you meet the criteria, your GP prescribing Mounjaro on the NHS is a real possibility, but only within those tightly defined cohorts, and waiting times vary by area. For people who fall outside the current NHS criteria or who do not want to wait, a private prescription is the lawful alternative, and our guide on whether your doctor can prescribe Mounjaro explains what to expect from that conversation.

Mounjaro treatment through a private regulated pharmacy follows the same clinical standards (assessment, prescriber sign-off, identity verification) without the NHS cohort restrictions. The Mounjaro overview page explains how the full treatment pathway works in private practice.

What the prescribing process involves wherever you go

Regardless of whether the prescriber is your GP or a clinician at an online pharmacy, the legal and clinical requirements are the same. You cannot lawfully receive Mounjaro without a valid prescription, and a valid prescription requires a prescriber to have assessed you, your weight, your relevant medical history, your current medicines, and any conditions that might affect suitability or safety. If you are unsure about the rules around this, our page on whether doctors can prescribe Mounjaro sets out the full picture of how prescribing authority works in the UK.

At a private regulated service like nume, that assessment is carried out by a GPhC-registered Independent Prescriber, a real clinician reviewing your answers the same day, not automated software. Identity is verified by photo ID, and weight is confirmed on a live video call. That matters because the prescriber is making a genuine clinical decision, not processing a form. Once approved, the prescription is issued and the medicine is dispensed from our GPhC-registered UK pharmacy (registration number 9012878, verifiable at the GPhC register), sourced through the licensed UK supply chain.

For anyone wondering about cost, the Eli Lilly price increase in 2025 changed the market significantly. Eli Lilly raised its UK list prices from September 2025, and private treatment now typically ranges from around £149 to £375 per month depending on dose and provider. More detail on how private pricing works is on the treatment page. What matters clinically is that the supply chain is legitimate and the prescriber is registered, not who quotes the lowest number.

The NHS medicines page for tirzepatide on the NHS website is the right place to read the patient-level information about what the medicine does and what to expect. Our FAQs page covers common questions about the private prescription process specifically.